Literature DB >> 18762724

Intraocular pressure lowering effect of once daily versus once weekly latanoprost instillation in the same normal individuals.

Urtogtah Darhad1, Makoto Nakamura, Miyuki Fujioka, Yasuko Tatsumi, Azusa Nagai-Kusuhara, Hidetaka Maeda, Akira Negi.   

Abstract

This study tested whether once weekly instillation of latanoprost exerts the similar IOP lowering effect as once daily instillation in the same individuals. Latanoprost was administered on right eyes of eight healthy male volunteers once daily first for 24 days, which was followed by the 31-day washout and the subsequent once weekly instillation for another 24 days. The mean baseline IOP was 12.06 +/- 1.50 (range, 10.0 to 14.0) mmHg, whereas the mean IOP during once daily treatment was 9.87 +/- 1.71 mmHg, which was significantly lower than the former (p=0.025). The mean washout IOP was 12.56 +/- 2.16 mmHg, which was similar to the baseline IOP. The mean IOP during once weekly instillation of latanoprost was 11.34 +/- 1.51 mmHg, which was not statistically different from the washout IOP. Four of the 8 subjects showed 15% or more reduction in IOP both during once daily and once weekly instillations, two of whom were overlapped. Since the magnitude of the IOP reduction with once daily use was higher than that with once weekly use even in the responders, the current protocol of once daily instillation should be respected.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762724

Source DB:  PubMed          Journal:  Kobe J Med Sci        ISSN: 0023-2513


  2 in total

1.  A Randomised Open Label Comparative Clinical Trial on the Efficacy of Latanoprost and Timolol in Primary Open Angle Glaucoma.

Authors:  Sharadashri Rao; P V Narayanan
Journal:  J Clin Diagn Res       Date:  2016-01-01

2.  Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.

Authors:  Makoto Araie; Baldo Scassellati Sforzolini; Jason Vittitow; Robert N Weinreb
Journal:  Adv Ther       Date:  2015-11-12       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.